Solid Biosciences Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Solid Biosciences Inc. (SLDB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 14.24 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Solid Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.27M shares, a 57.51% increase year-over-year.
- Solid Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 10.41M shares, a 51.38% increase year-over-year.
- Solid Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 8.72M shares, a 29.92% increase year-over-year.
- Solid Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 8.43M shares, a 89.76% increase year-over-year.
- Solid Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 10.54M shares, a 53.54% increase from fiscal 2024.
- Solid Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 6.86M shares, a 118.83% increase from fiscal 2023.
- Solid Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 3.14M shares, a 61.15% increase from fiscal 2022.
- Solid Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 1.95M shares, a 347.66% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 14.24M shares 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | 13.27M shares 10-Q · filed 2026-05-12 | |||||||
| 2025-12-31 | 10.54M shares 10-K · filed 2026-03-19 | |||||||
| 2025-09-30 | 10.41M shares 10-Q · filed 2025-11-03 | 10.41M shares 10-Q · filed 2025-11-03 | ||||||
| 2025-06-30 | 8.72M shares 10-Q · filed 2025-08-12 | 8.72M shares 10-Q · filed 2026-08-06 | ||||||
| 2025-03-31 | 8.43M shares 10-Q · filed 2026-05-12 | |||||||
| 2024-12-31 | 6.86M shares 10-K · filed 2026-03-19 | |||||||
| 2024-09-30 | 6.88M shares 10-Q · filed 2025-11-03 | 6.88M shares 10-Q · filed 2025-11-03 | ||||||
| 2024-06-30 | 6.71M shares 10-Q · filed 2025-08-12 | 6.71M shares 10-Q · filed 2025-08-12 | ||||||
| 2024-03-31 | 4.44M shares 10-Q · filed 2025-05-15 | |||||||
| 2023-12-31 | 3.14M shares 10-K · filed 2025-03-06 | |||||||
| 2023-09-30 | 3.14M shares 10-Q · filed 2024-11-06 | 3.14M shares 10-Q · filed 2024-11-06 | ||||||
| 2023-06-30 | 3.19M shares 10-Q · filed 2024-08-13 | 3.19M shares 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | 2.96M shares 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | 1.95M shares 10-K · filed 2024-03-13 | |||||||
| 2022-09-30 | 701.95K shares 10-Q · filed 2023-11-08 | |||||||
| 2022-06-30 | 1.95M shares 10-Q · filed 2023-08-14 | 11.25M shares 10-Q · filed 2022-08-11 | ||||||
| 2022-03-31 | 1.95M shares 10-Q · filed 2023-05-11 | 10.05M shares 10-Q · filed 2022-04-27 | ||||||
| 2021-12-31 | 434.82K shares 10-K · filed 2024-03-13 | 6.52M shares 10-K · filed 2022-03-14 | ||||||
| 2021-09-30 | 416.31K shares 10-Q · filed 2022-11-10 | 6.24M shares 10-Q · filed 2021-11-03 | ||||||
| 2021-06-30 | 5.93M shares 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | 5.42M shares 10-Q · filed 2022-04-27 | |||||||
| 2020-12-31 | 273.75K shares 10-K · filed 2023-03-23 | 4.11M shares 10-K · filed 2021-03-15 | ||||||
| 2020-09-30 | 4.68M shares 10-Q · filed 2020-11-05 | 4.68M shares 10-Q · filed 2021-11-03 | ||||||
| 2020-06-30 | 5.21M shares 10-Q · filed 2021-08-16 | |||||||
| 2020-03-31 | 4.33M shares 10-Q · filed 2021-05-14 | |||||||
| 2019-12-31 | 3.21M shares 10-K · filed 2022-03-14 | |||||||
| 2019-09-30 | 3.36M shares 10-Q · filed 2020-11-05 | 3.36M shares 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | 3.25M shares 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | 3.28M shares 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | 1.90M shares 10-K · filed 2021-03-15 | |||||||
| 2018-09-30 | 1.85M shares 10-Q · filed 2019-11-12 | 1.85M shares 10-Q · filed 2019-11-12 | ||||||
| 2018-06-30 | 1.70M shares 10-Q · filed 2018-08-10 | 1.70M shares 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | 1.62M shares 10-Q · filed 2019-05-13 | |||||||
| 2017-12-31 | 1.40M shares 10-K · filed 2020-03-12 | |||||||
| 2017-09-30 | 2.09M shares 10-Q · filed 2018-11-13 | 2.09M shares 10-Q · filed 2018-11-13 | ||||||
| 2017-06-30 | 1.94M shares 10-Q · filed 2018-08-10 | 1.94M shares 10-Q · filed 2018-08-10 | ||||||
| 2017-03-31 | 1.63M shares 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | 1.10M shares 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |